Key result
Transcatheter mitral valve implantation had similar 30-day mortality compared to repeat surgery, but resulted in worse survival after four years.
Why the study?
TMVI has emerged as a less invasive alternative to repeated mitral valve surgery for pathology after prior ring or bioprosthetic implantation, but early and mid-term comparative outcomes required evaluation.
Does transcatheter mitral valve implantation improve early and long-term survival in patients with recurrent mitral valve disease compared to repeated mitral valve surgery?
Cohort (n=41)
No
Does transcatheter mitral valve implantation improve early and long-term survival in patients with recurrent mitral valve disease compared to repeated mitral valve surgery?
While transcatheter mitral valve replacement provides a less invasive alternative with comparable early mortality to repeat surgery, its significant drop in survival after four years underscores the continued primary role of surgery when feasible.
Answers are grounded in this paper and cite their sources.
TMVI may suit prohibitive-risk patients for early recovery; leaves open long-term survival advantage of surgery pending randomized data.
Background: In recent years, the use of transcatheter valve-in-valve implantation in the mitral position (TMVI) for the treatment of mitral valve pathology following ring or bioprosthetic implantation has emerged as a less invasive option in comparison to repeated mitral valve surgery (RMVS). We aimed to compare the early and mid-term results of these two strategies. Method: We retrospectively analyzed all patients who underwent a mitral intervention in our institution between 2005 and 2022. Applying the exclusion criteria, 41 subjects were analyzed: 23 underwent RMVS, while 18 underwent a TMVI. The time-dependency treatment effect was approached using a landmark analysis, applying the Kaplan–Meier analysis at different time points. Results: The two study groups were comparable in terms of age (p = 0.18), gender (p = 0.78), body surface area (p = 0.33), and EuroSCORE II (p = 0.06). No patients died perioperatively or had a stroke. Two patients in each group died within the first 30 days following the procedure (RMVS 8.3% vs. TMVI 11.1%; p = 0.75). Eighteen patients had died at follow-up; two underwent re-intervention on their mitral valve (one in each group). The mean survival was not statistically different between groups (RMVS 8 ± 1.1 years, 95% CI 5.8–10.2, vs. TMVI 4.79 ± 0.82 years, 95% CI 3.1–6.4; log-rank = 0.087). A landmark analysis of survival after four years showed significantly worse survival for patients in the TMVI group in comparison with those treated surgically (log-rank = 0.047). Conclusions: TMVI and RMVS are both effective strategies with similar short-term outcomes. However, patients in the TMVI group showed a significantly lower survival rate after four years.
No takes yet. Share an insight, caveat, or question.
Pollari et al. (2024) conducted a cohort in Recurrent mitral valve disease or prosthetic failure (n=41). Transcatheter mitral valve implantation (TMVI) vs. Repeated mitral valve surgery (RMVS) was evaluated on 30-day all-cause mortality (p=0.75). Transcatheter mitral valve implantation had similar 30-day mortality compared to repeat surgery, but resulted in worse survival after four years.
Synapse has enriched 10 related papers. Consider them for comparative context: